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Objective:This study compared the hospital and follow-up costs of patients who have undergone endovascular (EVAR) or
open (OR) elective abdominal aortic aneurysm repair.
Methods: The records of 195 patients (EVAR, n  55; OR, n  140) who underwent elective aortic aneurysm repair
between 1995 and 2004 were reviewed. Primary costing data were analyzed for 54 EVAR and 135 OR patients. Hospital
costs were divided into preoperative, operative, and postoperative costs. Follow-up costs for EVAR patients were
recorded, with a median follow-up time of 12 months.
Results:Mean preoperative costs were slightly higher in the EVAR group (AU$961/US $733 vs AU $869/US $663; not
significant). Operative costs were significantly higher in the EVAR group (AU $16,124/US $12,297 vs AU $6077/US
$4635; P< .001); this was entirely due to the increased cost of the endograft (AU $10,181/US $7,765 for EVAR vs AU
$476/US $363 for OR). Postoperative costs were significantly reduced in the EVAR group (AU $4719/US $3599 vs
AU$11,491/US $8,764; P< .001). Total hospital costs were significantly greater in the EVAR group (AU$21,804/US
$16,631 vs AU $18,437/US $14,063; P < .001). The increase in total hospital costs was due to a significant difference
in graft costs, which was not offset by reduced postoperative costs. The average follow-up cost per year after EVAR was
AU $1316/US $999. At 1 year of follow-up, EVAR remained significantly more expensive than OR (AU $23,120/US
$17,640 vs AU $18,510/US $14,122; P < .001); this cost discrepancy increased with a longer follow-up.
Conclusions: EVAR results in significantly greater hospital costs compared with OR, despite reduced hospital and
intensive care unit stays. The inclusion of follow-up costs further increases the cost disparity between EVAR and OR.
Because EVAR requires lifelong surveillance and has a high rate of reintervention, follow-up costs must be included in any
cost comparison of EVAR and OR. The economic cost, as well as the efficacy, of new technologies such as EVARmust be
addressed before their widespread use is advocated. (J Vasc Surg 2005;42:912-8.)Endovascular repair of abdominal aortic aneurysms
(EVAR) has become an increasingly popular alternative to
open repair (OR). Patients considered suitable candidates
for EVAR have increased from initial rates of 20% of re-
ferred patients1 to 68% in recent years.2 Interested surgeons
and manufacturers allege that patients are increasingly re-
questing this procedure because they are attracted to the
concept of minimally invasive surgery. With increasing
numbers of patients undergoing EVAR,3 questions of cost
are paramount to the clinician, hospital, and society.
Early studies reported that EVAR was less costly4,5 or
equivalent6,7 in cost to OR because of reduced lengths of
hospital stay and fewer intensive care unit (ICU) admis-
sions. These studies, however, were performed within the
context of clinical trials, and the costs of the endografts
were significantly less than in the current commercial envi-
ronment. Most later studies8-13 have reported higher hos-
pital costs for EVAR. Nonetheless, conflicting results re-
main. Studies that have used Markov decision modeling to
From the Canberra Hospital,a Departments of Vascular Surgeryb and Radi-
ology,c The Canberra Hospital, and Australian National University.d
Competition of interest: none.
Reprint requests: D. T. A. Hardman, FRACS, Department of Vascular
Surgery, The Canberra Hospital, Woden, ACT 2606, Australia (e-mail:
dtah@webone.com.au).
0741-5214/$30.00
Copyright © 2005 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.07.039
912evaluate cost-effectiveness14,15 have found EVAR to be a
cost-effective alternative to OR. Rosenberg et al16 reported
that EVAR was more profitable for a hospital than OR if
indirect costs were excluded from analysis.
Many previous studies have used costing estimates,13 have
relied on clinical coding by medical records staff to obtain
costs,12 or have reported cost differences only.6,11,13,17 To
date, most studies have been conducted in American hospi-
tals, where indirect costs are significantly higher than in Aus-
tralian, Canadian, and European hospitals.18
Only two costing studies comparing EVAR and OR8,9
have included follow-up costs in their analysis. This is a
considerable oversight because follow-up costs contribute
significantly to the overall cost of EVAR. In contrast toOR,
which requires little or no long-term follow-up,19 the du-
rability of EVAR remains uncertain. Long-term surveil-
lance is considered mandatory after EVAR20; thus, any
meaningful costing analysis of EVAR vs OR must include
follow-up costs.
METHODS
Between January 1, 1995, and December 31, 2004,
195 patients underwent elective infrarenal abdominal aor-
tic aneurysm repair (all EVARs were performed after 1998).
The treating surgeon, in consultation with an interven-
tional radiologist, determined the selection of EVAR or
OR. EVAR was performed on the basis of anatomic selec-
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formed by one of two vascular surgeons (D.T.A.H. or
S.R.B.). EVARs were performed by one surgeon and one of
two radiologists (R.J.A. orM.G.). All patient follow-up was
performed by these two surgeons.
Patients were generally admitted 1 day before EVAR or
OR. EVARs were performed by using a bifemoral approach
with patients under general anesthesia. Zenith (Cook,
Bloomington, Ind; n  40), Excluder (W.L. Gore &
Associates, Flagstaff, Ariz; n 14), or Talent (Medtronic/
AVE, Santa Rosa, Calif; n  1) aortobi-iliac endografts
were placed under fluoroscopic guidance. OR was per-
formed by using a transperitoneal approach and a Dacron
(DuPont, Wilmington, Del) straight (n 93) or bifurcated
(n  47) graft was implanted.
Hospital and surgeon records were reviewed to obtain
clinical characteristics, operative details, complications,
outcome parameters, and the need for readmissions or
additional procedures. Outcome parameters were defined
according to the Ad Hoc Committee for Standardized
Reporting Practices in Vascular Surgery.21
The cost for each patient was determined by reviewing
the medical records, the pathology system, and the medical
imaging system. For each patient, the total hospital cost was
divided into preoperative costs, operative costs, and post-
operative costs. Follow-up costs were obtained from dis-
charge until December 31, 2004, by using hospital medical
records, medical imaging department records, and sur-
geons’ records.
The Canberra Hospital is a tertiary referral public hos-
pital. Because of the system of federal government funding
of public hospitals in Australia, hospital costs are not as-
signed to individual patients. Wherever possible, exact costs
for individual patients were recorded. Other costs were
derived by using a costing model or the best available
estimate, described below. All costs were expressed in Aus-
tralian dollars and were normalized to 2003/2004 prices to
provide a picture of what is currently the real cost of
performing EVAR and OR. Equivalent costs in US dollars
(calculated at current exchange rates) are also reported.
Preoperative costs included pathology, standard car-
diorespiratory investigations (chest radiograph, electro-
cardiogram, and spirometry), consultations (including
physiotherapy), bed costs, and other investigations or
interventions (such as internal iliac artery aneurysm embo-
lization before EVAR) performed during the hospital ad-
mission. Operative costs included graft costs; additional
guidewires, catheters, and sheaths required for EVAR; and
operating room costs. Graft costs were obtained for each
patient from the manufacturers. For patients undergoing
EVAR, the cost of the guidewires, sheaths, catheters, and
contrast used in a typical procedure were added. Operative
room costs included allocations for operating room time,
anesthetic and nursing time, recovery time, drugs, and
surgical supplies. Operative costs for individual patients
were available only from 2003. From an analysis of the 21
patients who underwent OR and 18 patients who under-
went EVAR in the 2003 to 2004 financial year, a per-minute average operative cost was calculated. For each
patient in the study, the operative time in minutes was
multiplied by the per-minute cost; the surgeon’s fee, ac-
cording to the 2004 Medicare Benefits Schedule (MBS)
rebate, was added to this to obtain the total operating room
cost.
Postoperative costs included bed and nursing costs,
pathology, medical imaging, cardiorespiratory investiga-
tions and interventions, specialist consultations, allied
health costs, pharmacy costs, and additional costs, such as a
return to the operating room. Bed and nursing costs were
calculated by using details of expenditure from The Can-
berra Hospital Financial Services Department 2003 to
2004 budget. Employee expenses, operating expenses, and
allocated indirect expenses were calculated to obtain an
average cost per bed-day for an ICU bed, coronary care
bed, and vascular ward bed. This was multiplied by the
number of nights each patient spent in each location.
The number and type of pathology, radiology, and
cardiorespiratory investigations performed, the number of
specialist consultations, and the number of allied health
visits were determined for each patient, and costs were
calculated by using the 2004 MBS rate for hospital inpa-
tients. To gain an estimate of pharmacy costs, 20 patients
were randomly selected, and the cost of each drug admin-
istered during their admission was calculated. The total
pharmacy cost was divided by the number of days of
hospital stay to gain an average pharmacy cost per day,
which was used to derive the pharmacy cost for each
patient in the study. Costs associated with a return to the
operating room or interventional radiology procedures
were added to the postoperative costs for two EVAR and
seven OR patients.
Follow-up costs were obtained for the 54 EVAR pa-
tients discharged from the hospital. The annual number of
specialist visits, computed tomographic (CT) scans, angio-
grams, and interventional radiology procedures required to
treat endoleaks were recorded for each patient. Costs were
determined from the MBS and were discounted at a rate
of 3% per year to reflect the greater value of the dollar
currently compared with its future value.22 Total follow-
up time was calculated for each patient, and the mean
follow-up cost per year was calculated.
Statistical outliers (EVAR, n  1; OR, n  3) of more
than 3 SD from the mean for total hospital cost were
excluded from the primary analysis. Two patients in the OR
group who were transferred to a private hospital were also
excluded from costing analysis because complete financial
records were unavailable.
For normally distributed data, means are reported.Where
the data did not fit a normal distribution (Kolmogorov-
Smirnov test; P .05), medians are reported with ranges. For
the two groups, parametric data were compared by using the
Student t test, and for non-normally distributed data, the
Wilcoxon rank sum test was used. For proportions, the 2 test
was used. A P value .05 was considered statistically signifi-
cant.
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Clinical characteristics and outcome parameters.
During the 10-year period, 55 patients underwent EVAR,
and 140 patients underwent OR. The clinical characteris-
tics of the patients in the two groups are shown in Table I.
The mean age of the patients in the EVAR group was
higher (74.5 vs 71.0 years; P  .003), and there was a
higher incidence of chronic obstructive airway disease in
the EVAR group (44% vs 28%; P  .03). There was no
significant difference between the groups in the other char-
acteristics examined.
EVAR resulted in a reduced hospital stay and a reduced
need for ICU admission (Table II). The median length of
hospital stay in the EVAR group was 6 days (range, 4-24
days) and in the OR group was 10 days (range, 6-46 days;
P  .001). Only 11 (20%) of the EVAR patients were
admitted to the ICU after surgery, with a median ICU stay
of 0 days (range, 0-3 days) in the EVAR group compared
with 1 day (range, 1-19 days; P  .001) in the OR group.
There was a significant difference in the operation time
between the groups (mean, 135 minutes for EVAR vs 150
minutes for OR; P  0.045). There was no significant
difference in 30-day mortality between the groups (1.8%
Table I. Clinical characteristics of patients undergoing EV
Clinical characteristic
Endovascul
(n  55)
Age, y, mean  SD (range) 74.5  7.2 (5
Sex (M/F) 50/5 (91%/
Aneurysm diameter, mm (mean) 59
Smoking history 46 (84%)
Diabetes mellitus 10 (18%)
Cardiac disease 27 (49%)
Chronic airway disease 24 (44%)
Hypertension 39 (71%)
Hypercholesterolemia 31 (56%)
Renal impairment 9 (16%)
Cerebrovascular disease 6 (11%)
Peripheral vascular disease 15 (27%)
Malignant disease 11 (20%)
ASA grade II 16 (29%)
ASA grade III 34 (62%)
ASA grade IV 5 (9%)
EVAR, Endovascular aneurysm repair; OR, open repair; NS, not significan
*The 95% confidence interval of the difference was 5.81 to 1.17.
Table II. Outcome parameters for patients undergoing E
Outcome parameter
En
(
Length of hospital stay, d, median (range) 6
Need for ICU (No. of patients) 11
Length of ICU stay, d, median (range) 0
Length of operation, min (mean  SD) 1
30-d mortality 1
Mortality/severe complications 6
EVAR, Endovascular aneurysm repair; OR, open repair; ICU, intensive carfor EVAR vs 1.4% forOR) or in the number of patients whodied or experienced a severe complication (10.9% for
EVAR vs 10.0% for OR).
Two patients in the EVAR group were converted to
OR—the first as a result of rupture of the external iliac
artery during attempted graft placement and the second as
a result of an inability to pass guidewires through the iliac
arteries. These patients were analyzed in the EVAR group
and OR
Open
(n  140) P value
71.0  7.5 (53-89) .003*
113/27 (81%/19%) NS
60 NS
122 (87%) NS
18 (13%) NS
67 (48%) NS
39 (28%) .03
97 (69%) NS
71 (51%) NS
22 (16%) NS
12 (9%) NS
28 (20%) NS
15 (11%) NS
50 (36%)
86 (61%) NS
4 (3%)
,  American Society of Anesthesiology (anesthetic status classification).
and OR
cular
5)
Open
(n  140) P value
4) 10 (6-46) .001
) 140 (100%) .001
) 1 (1-19) .001
56 150  40 .045
%) 2 (1.4%) NS
9%) 14 (10.0%) NS
; NS, not significant.
Table III. Mean preoperative costs for patients
undergoing EVAR and OR
Cost component
Endovascular
(n  54)
Open
(n  135)
Pathology AU $140/US $107 AU $143/US $109
Cardiorespiratory
investigations AU $54/US $41 AU $54/US $41
Consultations AU $4/US $3 AU $27/US $21
Other investigations/
interventions AU $181/US $138 AU $39/US $30
Bed/nursing costs AU $539/US $411 AU $603/US $460
Total AU $961/US $733 AU $869/US $663
EVAR, Endovascular aneurysm repair; OR, open repair.AR
ar
8-89)
9%)VAR
dovas
n  5
(4-2
(20%
(0-3
35 
(1.8
(10.on an intention-to-treat basis.
le.
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higher in the EVAR group (AU $961/US $733 vs AU
$869/US $663; Table III). This was largely due to six
patients who required embolization of an internal iliac
artery aneurysm before EVAR (cost, AU $1635/US
$1241). If these patients were excluded from analysis, the
mean preoperative cost in the EVAR group was AU
$774/US $587. Costs for pathology, cardiorespiratory
investigations, consultations, and bed/nursing care were
similar between groups.
Operative costs were substantially higher in the EVAR
group (AU $16,124/US $12,297 vs AU $6077/US $4635;
Table IV). This was entirely due to the high cost of the
endograft, which was on average 21 times more expensive
than the open graft (AU $10,181/US $7,765 vs AU
$476/US $363). Endograft costs in this study ranged
from AU $9,500 to $15,481 (US $7,211-$11,751).
Operating room costs were similar between the two
groups (AU $5447/US $4154 for EVAR vs AU
$5608/US $4277 for OR).
The mean postoperative cost was reduced by a factor of
2.4 in the EVAR group (AU $4719/US $3599 for EVAR
vs AU $11,491/US $8,764 for OR; Table V). There was a
decrease in the cost of bed/nursing care (AU $3892/US
$2968 for EVAR vs AU $9997/US $7624 for OR); this
was due to both a reduced length of stay and a reduced ICU
stay. Pathology costs, medical imaging costs, cardiorespira-
tory costs, allied health costs, and pharmacy costs were also
less in the EVAR group. Two patients in the EVAR group
Table IV. Mean operative costs for patients undergoing E
Cost component
End
(n
Graft cost AU $10,18
Guide wires, sheaths, etc AU $497/
Operating room cost AU $5,447
Total AU $16,12
EVAR, Endovascular aneurysm repair; OR, open repair; N/A, not applicab
Table V. Mean postoperative costs for patients undergoin
Cost component
E
Bed/nursing AU $3
Pathology AU $2
Medical imaging AU $1
Cardiorespiratory interventions AU $1
Specialist consultations AU $3
Allied health consultations AU $1
Pharmacy AU $1
Return to operating room AU $3
Total AU $4
EVAR, Endovascular aneurysm repair; OR, open repair.and seven patients in the OR group required a return to theoperating room. Return to operating room costs did not
significantly alter the mean postoperative costs.
Total hospital costswere significantly greater in theEVAR
group (AU $21,804/US $16,631 vs AU $18,437/US
$14,063; P  .001; Table VI). The increase in total hospital
costs was due to a significant difference in graft costs (and,
hence, operative costs), which was not offset by reduced
postoperative costs. The mean cost of the graft accounted
for 47% of the total hospital cost in the EVAR group,
compared with 3% in the OR group.
Total costs including follow-up. Patients in the
EVAR group were routinely followed up by CT angiogram
at 1, 6, and 12 months after surgery and then yearly
thereafter. Two patients with impaired renal function were
followed up by Doppler ultrasonography. With a median
follow-up time of 12 months (range: 2-64 months), the
endoleak rate was 27.8% (type I, n 1; type II, n 13; type
III, n  1). Ten patients with endoleaks were treated with
interventional radiologic techniques. No patient has re-
quired conversion to OR, and there have been no cases of
aneurysm rupture to date.
Yearly follow-up costs for the patients discharged after
EVAR are shown in Table VII. Mean yearly costs were
similar for the first 3 years after surgery. The total cost of
follow-up for the 54 EVAR patients was AU $99,040/US
$75,208 over a total of 903 months. Thus, the average
follow-up cost per year after EVAR was AU $1316/US
$999. The mean total follow-up cost for patients in the OR
group was estimated at AU $73/US $55. At the 1-year
and OR
ular
)
Open
(n  135)
S $7,765 AU $476/US $363
399 N/A
$4,154 AU $5,608/US $4,277
S $12,297 AU $6,077/US $4,635
AR and OR
scular
54)
Open
(n  135)
US $2,968 AU $9,997/US $7,624
S $156 AU $483/US $368
S $138 AU $238/US $181
$11 AU $71/US $54
$26 AU $46/US $35
S $119 AU $274/US $209
S $99 AU $237/US $181
$24 AU $13/US $10
US $3,599 AU $11,491/US $8,764VAR
ovasc
 54
1/U
US $
/US
4/Ug EV
ndova
(n 
,892/
04/U
81/U
4/US
4/US
56/U
30/U
2/US
,719/follow-up, EVAR remained significantly more costly than
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$14,122; P  .001; Table VIII). This cost discrepancy will
further increase with longer follow-up.
DISCUSSION
As the number of patients undergoing EVAR increases,
questions regarding cost are becoming more pertinent. In
this study, we compared the hospital costs of EVAR and
OR and the follow-up costs for patients undergoing EVAR
to gain a picture of the total cost of this technology. Total
hospital costs were significantly higher for EVAR (AU
$21,804/US $16,631) than for OR (AU $18,437/US
$14,063). Although there was a reduction in postoperative
costs because of a reduced length of stay and reduced costs
associated with pathology, medical imaging, pharmacy, and
allied health costs, this difference did not recoup the large
cost of the endovascular graft. The mean cost of the endo-
vascular graft in this study was AU $10,181/US $7,765,
which accounted for 47% of the total hospital cost. At 1 year
of follow-up, EVAR cost AU $23,120/US $17,640, com-
Table VI. Component costs contributing to the mean tot
dollars)
Cost component
Endovascular
(n  54)
Pre-operative costs AUD $961/USD $733
Total operative costs AUD $16,124/USD $
Post-operative costs AUD $4,719/USD $3
TOTAL HOSPITAL COSTS AUD $21,804/USD $
Graft cost AUD $10,181/USD $
% graft of total cost 47%
NS  not significant.
Table VII. Follow-up costs after EVAR expressed as years
Year after EVAR No. Patients
Year 1 54 AU $
Year 2 23 AU $
Year 3 6 AU $
Year 4 2 AU $
Year 5 1 AU $
Year 6 1 AU $
EVAR, Endovascular aneurysm repair.
Table VIII. Hospital and follow-up costs of EVAR and O
Cost Endovascu
Hospital cost AU $21,804/U
Total cost at 1 y AU $23,120/U
Total cost at 2 y AU $24,436/U
EVAR, Endovascular aneurysm repair; OR, open repair.pared with AU $18,510/US $14,122 for OR. With longerfollow-up, the cost disparity between EVAR and OR in-
creased even further.
There are a number of limitations in this study, but we
do not believe that these would significantly affect the
overall results. We deliberately chose not to include prehos-
pital costs in our analysis, because the investigations re-
quired to decide eligibility for EVAR (CT angiogram and
aortogram) reflect the decision of whether to offer this
procedure, rather than the cost of the procedure itself.
Because the Australian public health system does not assign
hospital costs to individual patients, a few costs in this study
were necessarily derived from financial models or best avail-
able estimates by hospital accountants. We used the cost of
a “typical” procedure when estimating the cost of guide-
wires, sheaths, and catheters used for EVAR; this is likely to
underestimate the true operative cost of EVAR. In our
hospital, no record is kept of discarded guidewires, sheaths,
and catheters used in a particular procedure. The cost of the
radiologists’ time in performing EVAR was not included,
reflecting the fact that in many institutions EVAR is per-
spital cost for EVAR and OR (Australian dollars/US
Open
(n  135) P value
AUD $869/USD $663 NS
7 AUD $6,077/USD $4,635 .001
AUD $11,491/USD $8,764 .001
1 AUD $18,437/USD $14,063 .001
AUD $476/USD $363 .001
3%
e operation
ean
Range
AU $ US $
7/US $860 36-5,545 27-4,230
6/US $935 530-5,442 404-4,151
5/US $896 34-3,836 26-2,927
US $381 381-381 499-499
US $369 484-484 369-369
US $358 469-469 358-358
Open
,631 AU $18,437/US $14,063
,640 AU $18,510/US $14,122
,644 AU $18,510/US $14,122al ho
12,29
,599
16,63
7,765sinc
M
1,12
1,22
1,17
499/
484/
469/R
lar
S $16
S $17
S $18formed by either a vascular surgeon or a radiologist, but not
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crease the cost disparity between EVAR and OR.
Endograft cost is the primary determinant of
EVAR cost. It is clear that graft cost remains the largest
determinant of overall hospital costs for EVAR. Initial
studies in the late 1990s reported that EVAR was less
costly4,5 or equal in cost6,7 to OR. Those studies, however,
had small sample sizes and relatively low graft costs because
they were conducted within the context of clinical trials,
and grafts were provided to investigators at significantly
reduced prices. The US Food and Drug Administration
approved two endovascular devices in September 1999;
since then, the price of grafts has increased substantially.23
Almost all studies conducted since 1999 have shown EVAR
to be more costly, with grafts accounting for 52% to 78% of
the total hospital cost,8,9,12,13,16 compared with 20% to
38% in the two earlier studies.
In our study, the endograft accounted for 47% of the
total hospital cost, with a mean price of AU $10,181/US
$7,765. Previous studies have shown that a graft cost of less
than US $6000 is required for EVAR to be a on parity with
cost for OR.11,13 Our study agrees with these findings; with
a graft cost of US $6000 (AU $7550), the total hospital
cost for EVAR would have been equivalent to that of OR.
As more endografts receive US Food and Drug Adminis-
tration approval and as initial costs to companies associated
with research and development are recouped, prices of
endografts may be reduced. However, at the present time,
the price of the endograft is the primary cause of the
increased hospital cost of EVAR compared with OR.
Only one study since 1999 has found EVAR to be less
costly than OR. Rosenberg et al16 reported that EVAR was
more profitable than OR when costs were expressed as
“contribution margin per day.” The authors excluded hos-
pital overheads from their analysis, noting that overhead
cost allocation is often arbitrary and does not reflect the
true cost of the procedure. Nonetheless, hospital costs
remained higher in the EVAR group ($15,049 EVAR vs
$12,733OR). It was only because EVAR attracted a higher
rate of reimbursement and resulted in a reduced length of
stay that EVAR resulted in an increased contribution mar-
gin per day. The authors asserted that “hospitals should
seek to maximize the contribution margin per day of inpa-
tient duration of stay,” and from a hospital accounts per-
spective, this is certainly true; however, clinicians have a
responsibility not just to their hospital, but to society as a
whole. Similarly, studies that have analyzed costs relative to
diagnosis-related group refunds9,13,23 may be of interest to
a particular hospital but are less relevant to making deci-
sions about how widely EVAR should be implemented.
With limited health care dollars, clinicians must be mindful
of the overall cost of EVAR to the health care system.
Follow-up costs increase cost disparity after EVAR.
Hospital costs account for only part of the total cost of
EVAR. The possibility of endoleaks, graft migration, or
graft kinking requires lifelong follow-up,20 and secondary
vascular procedures are often required, adding substantiallyto costs. However, few previous studies have included
follow-up costs in their cost analysis.
Two studies have used Markov modeling to estimate the
cost-effectiveness of EVAR compared with OR. Patel et al 15
demonstrated that the cost of the initial hospitalization was
higher in the EVAR group compared with OR ($20,083 vs
$16,016), with an estimated lifetime cost of $28,901 in the
EVAR group. The study concluded that EVAR was a
cost-effective alternative if the graft cost was $8,000 to
$12,000 because of an increase in quality life-adjusted years
and the potential for decreased costs associated with major
long-term morbidities This study, however, assumed a
mortality and major morbidity rate of just 1.1% for EVAR,
compared with 8.8% for OR; no large trial to date has
reported such a low complication rate after EVAR. Bosch et
al14 reported that although lifetime costs were higher for
EVAR than OR ($39,785 vs $37,606), EVAR was a cost-
effective alternative if the complication rate was less than 5%
and the long-term failure rate was less than 13%. The
long-term failure rate after EVAR remains unknown, but a
reintervention for endoleak rate of approximately 7% per
year is commonly reported.24
Two costing studies comparing EVAR and OR have
included follow-up costs in their analysis. Birch et al9
reported a lifetime follow-up cost of AU $4120 per patient
in their group of 31 EVAR patients; however, it is uncertain
how these costs were derived and whether they included
the cost of treating endoleaks. Forbes et al8 included 2 to
14months of follow-up in their comparison of 7 EVAR and
31 OR patients. With an average of 5.4 CT scans per
patient, postoperative follow-up scans accounted for 16.3%
of the total cost of EVAR.
A further study25 followed up 77 patients undergoing
EVAR for a mean of 19.9 months. Estimated follow-up
costs were $3631 at 1 year and $9729 at 5 years. However,
the large number of procedures for endoleaks (27% of
patients) and the high rate of conversion to OR (9%) would
have markedly increased follow-up costs.
Our study estimated a mean follow-up cost after EVAR
of AU $1316/US $999 per year, including specialist con-
sultations, CT scans, and treatment of endoleaks by inter-
ventional techniques. Prinssen et al25 noted that “shorter
survival in [patients who died with a patent graft in place]
eliminates the increased costs of long term follow-up—ie.
cost-effectiveness appears to be greatest in this sub popula-
tion.” It is noteworthy that the youngest patient in our
study group, at age 58 (selected for EVAR because of a
horseshoe kidney), may incur lifetime follow-up costs of
AU $30,000. It is doubtful whether EVAR should be
offered routinely to patients of this age group, and EVAR
may prove to be cost-effective only in very elderly patients
or those with a reduced life expectancy. Further informa-
tion is needed to determine the true lifetime follow-up
costs after EVAR. It is clear, however, that follow-up costs
after EVAR are substantial and must be included in any
costing study.
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Economics plays an increasingly important role in
modern medical management, and clinicians should be
mindful of not only the efficacy of new technology, but also
its cost. Our study indicates that EVAR results in signifi-
cantly greater hospital costs compared with OR, despite
reduced hospital and ICU stays. The inclusion of follow-up
costs further increases the disparity between EVAR and
OR. Clinicians must be involved in assessing the cost-
benefit analysis of new techniques on a patient-by-patient
basis. If we fail to become involved in making such deci-
sions, they will be made by others on our behalf.
Thanks to David Dowling, of the Financial Services
Department at The Canberra Hospital, for his assistance in
obtaining hospital costing data.
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